glutathione and amblyopia - The Mother of All Antioxidants Congenital cataracts affect the retinal
Description
This timeline shows why having a robust Quality Management System is all-important for prompt, thorough corrective actions

Naunyn-Schmiedeberg's Arch Pharmacol 399 , 1298313008 (2026)

In vitro comparison of LL-37 and A 140 and A 142 demonstrates their comparable shared capabilities as a broad spectrum AMPs with bacteriostatic and/or bacteriocidal activity against a variety of bacteria and also fungi (Soscia et al., 2010)

Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, Stough D, DeVillez R, Rietschel R, Savin R, Bergfeld W, Swinehart J, Funicella T, Hordinsky M, Lowe N, Katz I, Lucky A, Drake L, Price VH, Weiss D, Whitmore E, Millikan L, Muller S, Gencheff C, Carrington P, Binkowitz B, Kotey P, He W, Bruno K, Jacobsen C, Terranella L, Gormley GJ, Kaufman KD
[65] demonstrated that bevacizumab, an anti-VEGF antibody, has efficacy in RCC, and over the past several years, there has been an increase in progression-free survival and quality of life in patients with metastatic RCC, which was attributed to the advent of the MTKIs [66, 67]

Researchers propose this mechanism could show selective toxicity toward cancer cells because: Tumor cells often lack catalase and other peroxide-neutralizing enzymes Cancer microenvironments contain elevated labile iron levels Normal cells maintain robust antioxidant defenses Clinical Trial Evidence Recent Phase II trials investigating vitamin C injections in cancer treatment have reported early signals that researchers describe as promising, though the evidence remains preliminary: Pancreatic Cancer Study: In a randomized Phase II trial of 34 patients with stage 4 metastatic pancreatic cancer led by Joseph Cullen at the University of IowaPharmacological ascorbate in combination with gemcitabine and nab-paclitaxel published in Redox Biology (2024)participants who received 75 grams (75,000 mg) of IV vitamin C three times weekly alongside standard chemotherapy reached a median overall survival of 16 months, compared with 8.3 months for chemotherapy alone
